Care Partners’ Perceptions of Amyloid-Targeting Therapy and Treat‑to‑Clearance for Alzheimer’s Disease in Japan: A Qualitative Study
These results suggest that providing clear explanations and facilitating shared decision-making when introducing ATT, as well as introducing follow-up care and long-term evidence after stopping treatment, are needed.
Authors
- Keisuke Suzuki (ORCID: https://orcid.org/0000-0001-5790-1289)
- Kanako Shimoura (ORCID: https://orcid.org/0000-0003-4315-9698)
- Naohisa Hatakeyama
- Kaname Ueda (ORCID: https://orcid.org/0000-0003-1967-9829)
- Masashi Tsujimoto (ORCID: https://orcid.org/0009-0009-1041-4470)
- Shintaro Suo
- Sadao Katayama
Institutions
- Inpex (Japan) (JP)
- Eli Lilly (Japan) (JP)
- Kurashiki Medical Center (JP)
- National Center for Geriatrics and Gerontology (JP)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1007/s40120-025-00869-w
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company